Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was the first drug to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…
Social Clips
https://www.youtube.com/watch?v=CfmkE6zqT9A “Dolores has Idiopathic Pulmonary Fibrosis (IPF) and tells her story about living with lung disease. Dolores found help in dealing with her illness by contacting the Irish Lung Fibrosis Association (ILA).” Learn more about IPF: https://bit.ly/1XjPFMa…
1. Esbriet’s Promise and Potential as a PF Therapy 2. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015 3. Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies …
Experimental IPF Therapies: Cotrimoxazole
Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad…
Pulmonary Fibrosis Foundation
“Patients, caregivers, and physicians discuss the disease and the role the Pulmonary Fibrosis Foundation has played in the past years.” Learn more about Pulmonary Fibrosis Foundation:Â https://bit.ly/1MkiSzf …
#TBT – Remembering Evel Knievel
Evel Knievel was an American daredevil, entertainer, and international icon. He attempted more than 75 ramp-to-ramp motorcycle jumps between 1965 and 1980, and in 1974, a canyon jump across Snake River Canyon (which failed) in a team-powered rocket. During his career, he suffered more than 433 bone fractures, which gave…
OFEV Efficacy Supported in a New Study
Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV ® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both…
Approved Pulmonary Fibrosis Therapies
Learn more about Approved IPF Therapies Ofev and Esbriet. Read more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
Last Week’s Most Read Posts On Pulmonary Fibrosis
1. Pulmonary Fibrosis Foundation Sets Scientific Record at Upcoming Summit 2. Lung Stem Cell Spheroids Could Offer Cheap, Rapid Pulmonary Fibrosis Therapy 3. Genentech to Help Support Pulmonary Fibrosis Foundation Programs…
“Dot Delarosa always had a challenging life, but things got worse when she found out that she had Pulmonary Fibrosis. She needed a lung transplant immediately, or she would die. This is her story.” Learn more Pulmonary Fibrosis:Â https://bit.ly/1lfMsiZ…
Your PF Community
Recommended Posts
- In preparing for emergencies, we’re using technology to our advantage
- US, EU regulators name deupirfenidone an orphan drug for treating IPF
- This month is our time to raise awareness about rare diseases
- Targeting ‘overlooked’ gene could lead to new treatments for IPF: Study
- Partner with PFF through advocacy and education to benefit PF community
